Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27006486 | 0.84 | ALDH1A1 (0.46) | LMNAMAPK14ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL8842846 | 0.84 | MAPK14 (0.47) | LMNAMAPK14ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL10958614 | 0.76 | RORB (0.44) | ALDH1A1SMN1; SMN2MAPTNPC1MAPK1 | |
| SCHEMBL30722868 | 0.76 | EIF4H (0.53) | LMNACA12CA1CA2CA9 | |
| SCHEMBL15153309 | 0.76 | LMNA (0.52) | LMNACA12CA1CA2CA9 | |
| SCHEMBL27006500 | 0.74 | CA12 (0.43) | LMNACA12CA1CA2CA9 | |
| SCHEMBL27006465 | 0.73 | STAT3 (0.49) | LMNACA12CA1CA2CA9 | |
| SCHEMBL1257365 | 0.72 | KDM4E (0.48) | LMNACA12CA1CA2CA9 | |
| SCHEMBL10959357 | 0.72 | MAPT (0.46) | ALDH1A1SMN1; SMN2HPGDKDM4EMAPT | |
| SCHEMBL31133143 | 0.71 | NPSR1 (0.43) | LMNAALDH1A1SMN1; SMN2HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4308558-A1 | MODULATORS OF FPR1 AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-01-24 | — | — | EP | disclosed |
| US-20240018124-A1 | MODULATORS OF FPR1 AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-01-18 | — | — | US | disclosed |
| US-20240018124-A1 | MODULATORS OF FPR1 AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-01-18 | — | — | US | disclosed |
| US-20240018124-A1 | MODULATORS OF FPR1 AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-01-18 | — | — | US | disclosed |
| CN-116981663-A | Modulators of FPR1 and methods of use thereof | 百放开曼有限公司 | 2023-10-31 | — | — | CN | disclosed |
| WO-2022193187-A1 | MODULATORS OF FPR1 AND METHODS OF USING SAME | BIOFRONT LTD. (CAYMAN) (KY) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022194240-A1 | MODULATORS OF FPR1 AND METHODS OF USING THE SAME | BIOFRONT LTD. (CAYMAN) (KY) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018124-A1 | MODULATORS OF FPR1 AND METHODS OF USING THE SAME | FPR1, FPR2, FPR3 | LMNA 3437/4885IKBKB 1621/4885CA12 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.